Showing 2644 results
- Key Release /In MONALEESA-3, Kisqali plus fulvestrant achieved statistically significant overall survival benefit vs. fulvestrant alone in postmenopausal women (HR=0.724; p=0.00455)[1] Kisqali is the only…
- Media Release /New interim data from SPR1NT study supports critical importance of early intervention in pre-symptomatic SMA patients, leading to age‑appropriate major milestone gainUpdated results from global…
- Media Release /Early combination treatment strategy with vildagliptin (Galvus®) and metformin was superior to standard of care in newly diagnosed type 2 diabetes patients[1],[2] The landmark VERIFY study is…
- Key Release /Phase III PREVENT study met 16-week primary endpoint of ASAS40 in patients with active non-radiographic axial spondyloarthritis (nr-axSpA). All secondary endpoints were also met [1] Novartis has…
- Media Release /Both ASCLEPIOS I and II studies met their primary endpoints in patients with relapsing forms of MS (RMS)[1]; overall ofatumumab (OMB157), a subcutaneous, potent, fully-human antibody targeting CD20…
- Media Release /Monitoring disease activity and treatment effectiveness in MS patients in real-time is a serious challenge for physicians New data show how the use of two central nervous system-derived…
- Media Release /New post hoc statistical analysis of the pivotal EXPAND study at ECTRIMS shows that Mayzent® (siponimod) can help patients keep their mobility for over four years longer on average *[1] …
- Media Release /Ph 3 STR1VE data show prolonged event-free survival, early and rapid increases in CHOP-INTEND and significant milestone achievement in SMA Type 1, consistent with START trial First-in-human…
- Media Release /By 2020, over 1.5 million people in the US are likely to have wet AMD, the leading cause of blindness in industrialized countries Filing is based on Phase III data from the HAWK and HARRIER…
- Media Library /
Pagination
- ‹ Previous page
- 1
- …
- 226
- 227
- 228
- 229
- 230
- 231
- 232
- …
- 265
- › Next page